Rz1–7 is a multimeric hammerhead ribozyme targeting seven unique sites within the human CCR5 mRNA that is active in vitro. Mouse stem cell virus-based MGIN and human immunodeficiency virus (HIV)-1-based HEG1 vectors were used to express Rz1–7 in a human CD4+ T lymphoid cell line. Stable transductants expressed Rz1–7, which was further shown to be active, since CCR5 mRNA and surface CCR5 protein expression levels decreased. High levels of progeny virus were produced when the transduced cells were challenged with an X4-tropic HIV-1 (NL4-3) strain, suggesting that Rz1–7 expression does not affect X4-tropic virus replication. When the transduced cells expressing Rz1–7 were challenged with the R5-tropic HIV-1 (BaL) strain, 99–100 % inhibition of progeny virus production was observed for the duration of the experiment (∼2 months). When the cells were precultured for 2–3 months prior to HIV-1 infection, inhibition was more prominent in cells transduced with MGIN-Rz1–7 than with HEG1-Rz1–7. Inhibition occurred at the level of viral entry, as no HIV-1 DNA could be detected. These results demonstrate that Rz1–7 confers excellent inhibition of R5-tropic HIV-1 replication at the level of entry. Therefore, we anticipate that this multimeric ribozyme will be beneficial for HIV-1 gene therapy.
AdachiA.,
GendelmanH. E.,
KoenigS.,
FolksT.,
WilleyR.,
RabsonA.,
MartinM. A.1986; Production of acquired immunodefiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59:284–291
BaiJ.,
GorantlaS.,
BandaN.,
CagnonL.,
RossiJ.,
AkkinaR.2000; Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo . Mol Ther 1:244–254[CrossRef]
BergerE. A.,
DomsR. W.,
FenyoE. M.,
KorberB. T.,
LittmanD. R.,
MooreJ. P.,
SattentauQ. J.,
SchuitemakerH.,
SodroskiJ.,
WeissR. A.1998; A new classification for HIV-1. Nature 391:240–245[CrossRef]
BurnsJ. C.,
FriedmannT.,
DrieverW.,
BurrascanoM.,
YeeJ. K.1993; VSV-G glycoprotein pseudotyped retroviral vectors: concentration to very high titre and efficient gene transfer into mammalian and non-mammalian cells. Proc Natl Acad Sci U S A 90:8033–8037[CrossRef]
CagnonL.,
RossiJ.2000; Downregulation of the CCR5 β chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts. Antisense Nucleic Acid Drug Dev 10:251–261[CrossRef]
ChengL.,
DuC.,
MurrayD.,
TongX.,
ZhangY. A.,
ChenB. P.,
HawleyR. G.1997; A GFP reporter system to assess gene transfer and expression in human hematopoietic progenitor cells. Gene Ther 4:1013–1022[CrossRef]
DeanM.,
CarringtonM.,
WinklerC.,
HuttleyG. A.,
SmithM. W.,
AllikmetsR.,
GoedertJ. J.,
BuchbinderS. P.,
VittinghoffE.other authors1996; Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273:1856–1862[CrossRef]
GartnerS.,
MarkovitsP.,
MarkovitzD. M.,
KaplanM. H.,
GalloR. C.,
PopovicP.1986; The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233:215–219[CrossRef]
HawleyR. G.1994; High-titer retroviral vectors for efficient transduction of functional genes into murine hematopoietic stem cells. Ann N Y Acad Sci 716:327–330
HuangY.,
PaxtonW. A.,
WolinskyS. M.,
NeumannA. U.,
ZhangL.,
HeT.,
KangS.,
CeradiniD.,
JinZ.other authors1996; The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2:1240–1243[CrossRef]
JeangK. T.,
BerkhoutB.1992; Kinetics of HIV-1 long terminal repeat trans -activation. Use of intragenic ribozyme to assess rate-limiting steps. J Biol Chem 267:17891–17892
KawabataK.,
UjikawaM.,
EgawaT.,
KawamotoH.,
TachibanaK.,
IizasaH.,
KatsuraY.,
KishimotoT.,
NagasawaT.1999; A cell autonomous requirement for CXCR4 in long-term lymphoid and myeloid reconstitution. Proc Natl Acad Sci U S A 96:5663–5667[CrossRef]
LamotheB.,
JoshiS.2000; Current developments and future prospects for HIV gene therapy using interfering RNA-based strategies. Front Biosci 5:D527–D555[CrossRef]
LiM. J.,
KimJ.,
LiS.,
ZaiaJ.,
YeeJ. K.,
AndersonJ.,
AkkinaR.,
RossiJ. J.2005; Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 12:900–909[CrossRef]
LiW.,
YuM.,
BaiL.,
BuD.,
XuX.2006; Downregulation of CCR5 expression on cells by recombinant adenovirus containing antisense CCR5, a possible measure to prevent HIV-1 from entering target cells. J Acquir Immune Defic Syndr 43:516–522
LiuR.,
PaxtonW. A.,
ChoeS.,
CeradiniD.,
MartinS. R.,
HorukR.,
MacDonaldM. E.,
StuhlmannH.,
KoupR. A.,
LandauN. R.1996; Homozygous defect in HIV-1 co-receptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell 86:367–377[CrossRef]
MartinezM. A.,
GutierrezA.,
Armand-UgonM.,
BlancoJ.,
PareraM.,
GomezJ.,
ClotetB.,
EsteJ. A.2002; Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 16:2385–2390[CrossRef]
MillerA. D.,
ButtimoreC.1986; Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 6:2895–2902
MokH. P.,
JavedS.,
LeverA.2007; Stable gene expression occurs from a minority of integrated HIV-1-based vectors: transcriptional silencing is present in the majority. Gene Ther 14:741–751[CrossRef]
NaldiniL.,
BlömerU.,
GallayP.,
OryD.,
MulliganR.,
GageF. H.,
VermaI. M.,
TronoD.1996; In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263–267[CrossRef]
OnaiN.,
ZhangY.,
YoneyamaH.,
KitamuraT.,
IshikawaS.,
MatsushimaK.2000; Impairment of lymphopoiesis and myelopoiesis in mice reconstituted with bone marrow-hematopoietic progenitor cells expressing SDF-1-intrakine. Blood 96:2074–2080
QinX. F.,
AnD. S.,
ChenI. S.,
BaltimoreD.2003; Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A 100:183–188[CrossRef]
RamezaniA.,
JoshiS.1996; Comparative analysis of five highly conserved sites within the HIV-1 RNA for their susceptibility to hammerhead ribozyme-mediated cleavage in vitro and in vivo . Antisense Nucleic Acid Drug Dev 6:229–235[CrossRef]
RamezaniA.,
MaX. Z.,
NazariR.,
JoshiS.2002; Development and testing of retroviral vectors expressing multimeric hammerhead ribozymes targeted against all major clades of HIV-1. Front Biosci 7:a29–a36[CrossRef]
StrayerD. S.,
AkkinaR.,
BunnellB. A.,
DropulicB.,
PlanellesV.,
PomerantzR. J.,
RossiJ. J.,
ZaiaJ. A.2005; Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther 11:823–842[CrossRef]
ZouY. R.,
KottmannA. H.,
KurodaM.,
TaniuchiI.,
LittmanD. R.1998; Function of the chemokine receptor CXCR4 in hematopoietic and in cerebellar development. Nature 393:595–599[CrossRef]